grant

Mutant Tubulins Confer Resistance to Pathological Tau

Organization SEATTLE INST FOR BIOMEDICAL/CLINICAL RESLocation SEATTLE, UNITED STATESPosted 1 Jul 2024Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2025AD dementiaAddressAffectAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimers DementiaAxonal TransportAxoplasmic TransportBehavioralBiochemicalBiology of AgingC elegansC. elegansC.elegansCRISPRCRISPR/Cas systemCaenorhabditis elegansCellular MatrixClinicalClustered Regularly Interspaced Short Palindromic RepeatsCommunitiesCytoskeletal SystemCytoskeletonDNA mutationDefectDegenerative Neurologic DisordersDevelopmentDiseaseDisease ProgressionDisorderEconomicsFTLDFrontal Temporal Lobar DegenerationFrontotemporal Lobar DegenerationsFrontotemporal variety lobar degenerationGenesGenetic ChangeGenetic defectGenetic mutationGoalsHealth CareHealth Care SystemsHumanIn VitroInvestigatorsJournalsKnowledgeLaboratoriesLeadershipMAPT geneMAPT proteinMT-bound tauMTBT1MagazineMeasuresMediatingMedicalMethodsMicro-tubuleMicrotubule PolymerizationMicrotubulesModelingModern ManMolecularMotilityMotorMutant Strains MiceMutationNerve CellsNerve DegenerationNerve UnitNervous System Degenerative DiseasesNeural CellNeural Degenerative DiseasesNeural degenerative DisordersNeurocyteNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeuron DegenerationNeuronal DysfunctionNeuronsPathologicPhasePhenotypePhosphorylationPlayPoint MutationPrevalencePrimary Senile Degenerative DementiaPrincipal InvestigatorProcessPropertyProtein PhosphorylationProteinsResearchResearch PersonnelResearch ResourcesResearchersResistanceResourcesRoleSystemTauopathiesTestingToxic effectToxicitiesTrainingTransgenic OrganismsTranslatingTranslationsTraumatic encephalopathyTubulinUnited States Department of Veterans AffairsUnited States Veterans AdministrationUniversitiesVeterans AdministrationVeterans AffairsWashingtonWorkabnormally aggregated tau proteinage associated diseaseage associated disorderage associated impairmentage dependent diseaseage dependent disorderage dependent impairmentage related human diseaseage-related diseaseage-related disorderage-related impairmentaged groupaged groupsaged individualaged individualsaged peopleaged personaged personsaged populationaged populationsaging populationbiophysical approachesbiophysical methodologybiophysical methodsbiophysical techniquescareercareer faircareer networkingchronic traumatic encephalopathydegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdevelopmentaleconomicexperimentexperimental researchexperimental studyexperimentsfilamentous tau inclusiongain of functiongene conservationgenetic approachgenetic strategygenome mutationimprovedinsoluble aggregateinterestintracellular skeletonlive cell imagelive cell imaginglive cellular imagelive cellular imagingmeetingmeetingsmicrotubule associated protein taumicrotubule associated protein tau aggregationmicrotubule associated protein tau depositmicrotubule bound taumicrotubule-associated protein taumicrotubule-bound taumouse mutantmutantneural degenerationneural dysfunctionneurodegenerationneurodegenerativeneurodegenerative illnessneurological degenerationneuronalneuronal degenerationneuropathologic tauneuropathological taunew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeutic targetnew therapy approachesnew therapy targetnew treatment approachnew treatment strategynovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeutic targetnovel therapy approachnovel therapy targetpaired helical filament of taupopulation agingprimary degenerative dementiaprofessional networkingprotein aggregateprotein aggregationreconstitutereconstitutionresistantself-aggregate tausenile dementia of the Alzheimer typeskillssocialsocial rolesoundspeed networkingtautau PHFtau Proteinstau accumulationtau aggregatetau aggregationtau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau factortau fibrillizationtau filamenttau induced degenerationtau induced neurodegenerationtau mediated neurodegenerationtau microtubule interactiontau neurodegenerative diseasetau neurofibrillary tangletau neuropathologytau oligomertau paired helical filamenttau pathologytau pathophysiologytau polymerizationtau proteinopathytau related neurodegenerationtau-MT interactiontau-induced pathologytau-microtubule interactiontau-tau interactiontauopathic neurodegenerative disordertauopathytooltransgenictranslationτ Proteinsτ aggregation
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary/Abstract
Pathological tau is present in a number of age-related diseases (tauopathies) including

Alzheimer's Disease (AD). With a rising aged population the prevalence of these diseases will

become an enormous healthcare, economic and social burden. To-date there are no clinically

proven disease altering treatments. Recently, we have discovered mutant tubulin modifies

tauopathy-like phenotypes in transgenic C. elegans models, reducing human tau-induced motility

deficits and neurodegeneration. We hypothesize that mutant tubulin ameliorates tau-induced

phenotypes in C. elegans by altering tau-microtubule interactions. To test our hypothesis we

propose to 1) use C. elegans to determine if the level of tubulin suppression is based in tubulin

expression level 2) use reconstituted in vitro systems to test whether tubulin mutations affect tau-

microtubule interactions and 3) use mammalian primary neurons to test whether mutant tubulin

impacts microtubule properties and function. The proposed projects will elucidate the

mechanisms of mutant tubulin suppression of tau induced-pathology and tau-microtubule

interactions. Additionally, this work will contribute greater understanding of the cytoskeleton in

neurodegenerative disease.

My goal is to develop a career as a principal investigator devoted to the discovery of the

molecular mechanisms underpinning tauopathies and the roles the cytoskeletal network play in

neurodegeneration. To accomplish this, my training plan focuses on 1) expanding my technical

toolkit to incorporate biophysical approaches and live cell imaging 2) gaining greater knowledge

in the biology of aging 3) improving skills in laboratory leadership and expanding my professional

network.

The University of Washington and the Veterans Affairs Puget Sound Health Care System

share an abundance of researchers interested in Alzheimer's and other neurodegenerative

conditions. There are substantial intellectual resources such as seminars, journal clubs and

meetings that create numerous opportunities broaden my perspective through interactions with

the medical and scientific community in AD-related research.

Grant Number: 5R00AG073455-05
NIH Institute/Center: NIH

Principal Investigator: Sarah Benbow

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →